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Abstract 
A significant number of pancreases procured for transplantation are deemed unsuitable due 
to concerns about graft quality and the associated risk of complications. However, this 
decision is subjective and some declined grafts may be suitable for transplantation. Ex vivo 
normothermic perfusion prior to transplantation may allow a more objective assessment of 
graft quality and reduce discard rates. We report ex vivo normothermic perfusion of human 
pancreases procured but declined for transplantation, with ABO-compatible warm oxygenated 
packed red blood cells for 1-2 hours. Five declined human pancreases were assessed using 
this technique after a median cold ischemia time of 13h19mins. One pancreas, with cold 
ischemia over 30 hours did not appear viable and was excluded. In the remaining pancreases 
blood flow and pH were maintained throughout perfusion. Insulin secretion was observed in 
all four pancreases, but was lowest in an older donation after cardiac death pancreas. 
Amylase levels were highest in a gland with significant fat infiltration. This is the first study to 
assess the perfusion, injury, as measured by amylase, and exocrine function of human 
pancreases using EVNP and demonstrates the feasibility of the approach, although further 
refinements are required. 
 
  
Introduction 
Pancreas transplantation is a potentially curative treatment for type I diabetes, but is severely 
limited by the lack of availability of suitable organs. Approximately 30% of pancreases 
procured from deceased donors in the United States (1) and 50% in the United Kingdom (UK) 
(2) are deemed unsuitable for transplantation and are discarded, most commonly because of 
concerns about major post-operative complications associated with use of suboptimal grafts. 
However, this decision is often subjective. In addition, a number of potentially suitable 
pancreases are never considered for transplantation as the donor does not fulfil agreed 
acceptance criteria, such as age.  
Furthermore, despite advances in operative technique and post-operative management, 
pancreas transplantation remains a high-risk procedure with a complication rate of 25-50% 
(3-5) and a re-laparotomy rate of approximately 20% (6). Graft pancreatitis arising from 
ischemia reperfusion injury is a major contributing factor to many of these complications and 
may result in peri-pancreatic fluid collections (7), vascular thrombosis (8) and bleeding 
necessitating further surgery, in addition to the risk of graft loss or recipient death. Factors 
thought to increase the risk of graft pancreatitis include increased cold preservation time (9), 
donor obesity (8,10) and donor age (10,11).  
Despite the significant adverse consequences of ischemia reperfusion injury in pancreas 
transplantation, there have been little or no advances in pancreas preservation techniques 
over recent years (12) and cold static storage remains the only technique in clinical use.  
Ex vivo normothermic perfusion (EVNP) of organs prior to transplantation has the potential to 
improve preservation, abrogate the effects of ischemia reperfusion injury, facilitate the 
administration of therapeutic interventions and allow more objective selection of grafts for 
transplantation. It has already been introduced into clinical practice by members of our group 
for the preservation of kidneys prior to transplantation (13,14) and by others for lungs (15). 
EVNP has also been shown to be feasible for viability testing of discarded human donor livers 
(16) and kidneys (17). To date, the only reports of EVNP of pancreases have been restricted 
to experimental animal models (18-21). Here we report the first use of EVNP to assess the 
function and viability of discarded human pancreases. 
Methods 
Five human pancreases procured for transplantation but deemed unsuitable for 
transplantation by all UK pancreas transplant centres were included in the study between 
February 2014 and November 2014. The study was approved by the local research ethics 
committee and NHS Blood and Transplant. Consent to use the pancreas for research was 
obtained from donor families.  
Procurement and back bench preparation  
The pancreases were all procured by one of the UK national organ procurement teams, using 
in situ perfusion with ice cold University of Wisconsin solution (CoStorSol
®
; Bridge To Life, 
London, UK). Organs were packed and stored in preservation fluid and transported on ice. On 
arrival at the study centre, back bench preparation was performed by an experienced 
member of the transplant team as for clinical transplantation. The spleen was removed and 
splenic vessels ligated; arterial reconstruction was performed with a donor iliac Y graft to the 
splenic and superior mesenteric arteries using 5-0 polypropylene sutures. An arterial cannula 
was secured in the common iliac portion of the Y graft. The small bowel mesentery was over-
sewn and excess peri-pancreatic tissue removed. A wide-bore catheter was inserted into the 
distal duodenum and secured with a purse-string suture. The pancreas was weighed on 
completion of back-bench preparation. Prior to EVNP the pancreas was flushed with cold 
Gelofusine (B. Braun, Sheffield, UK) and any obvious leaking vessels ligated with absorbable 
ligatures.  The portal vein was left to drain freely back into the reservoir. 
 
 
Perfusion circuit 
The perfusion circuit was developed by members of our group (MLN, SAH) for EVNP of the 
kidney, and is now in clinical use (13,14). It comprises customised paediatric cardiopulmonary 
bypass technology (Medtronic UK, Watford, UK) and is made up of an organ chamber, 
venous reservoir, Biopump 560 centrifugal blood pump, Affinity hollow fiber membrane 
oxygenator, ¼ inch PVC tubing and a Hirtz heat exchanger (Chalice Medical, 
Nottinghamshire, UK) (figure 1). The hardware includes a speed controller, TX50P flow 
transducer and a temperature probe (Cole-Palmer, London, UK). The system is pressure 
controlled, with variable flow due to auto-regulation by the organ. Pressure was set at 50-55 
mmHg and temperature maintained at 37°C. A 95% O2/5% CO2 gas mix flowing at 0.1L/min 
was used to oxygenate the perfusion solution. 
Perfusion solution 
The perfusate was blood-based; donor ABO-compatible packed red cells were obtained from 
the hospital blood bank. This was diluted with a matched volume of Gelofusine (B. Braun, 
Sheffield, UK) to obtain a hematocrit of around 20%. 8.4% sodium bicarbonate was added to 
normalize pH. Other additives were 20 ml of 10% mannitol (Baxter Healthcare, Thetford, UK), 
5 ml of 5% glucose (Baxter Healthcare) and 2,500 iu of heparin (CP Pharmaceuticals, 
Wrexham, UK). 
Outcome measures 
Prior to placing the organ on the circuit samples were taken for blood gas analysis (pH, pCO2, 
pO2, base excess, tCO2, and HCO3) and immediately analyzed (Opti CCA-TS Blood Gas 
System, Una Healthcare, Stoke on Trent, UK). Samples were also taken for biochemical 
assays (amylase, lipase, lactate dehydrogenase, insulin), placed in lithium heparin tubes on 
ice, centrifuged (10 minutes at 2000 rpm at 4°C) within 30 minutes of collection and stored at 
-80°C.  
During EVNP, blood flow, pressure, pump speed and temperature were regularly recorded. 
For the first two pancreases, samples for blood gas analysis and biochemistry were taken at 
30 minutes and then hourly. For the second two pancreases additional samples for 
biochemistry were taken every 5 minutes for the first 30 minutes of perfusion. At the end of 
perfusion insulin stimulation tests were performed. Firstly, 20mls of 5% glucose (Baxter 
Healthcare) was added as a bolus to the arterial limb of the circuit and samples taken for 
insulin at 1, 3 and 6 minutes following infusion. For the latter two pancreases, this was 
followed by a bolus of 250mg arginine (Sigma Aldrich, Gillingham, UK), with samples for 
insulin at 1, 3 and 6 minutes following infusion.  At the end of perfusion the pancreas was 
weighed and the volume of duodenal drainage was also noted.  
Insulin levels were measured using a one-step chemiluminescence immunoassay on a 
Diasorin Liaison XL automated immunoassay analyzer (Diasorin S.p.A, Saluggia, Italy). 
Amylase and lipase levels were determined using a colorimetric method on a Siemens 
Dimension RXL autoanalyzer (Siemens Healthcare, Camberley, UK). 
Histopathology 
On completion of EVNP mesenteric fat, vessels, duodenum and spleen were dissected from 
the pancreas and the gland sectioned at 1cm intervals. Representative sections from the 
head, body and tail were formalin-fixed and paraffin-embedded. Slides were stained with 
haematoxylin and eosin and were assessed for both pre-existing pathological changes and 
features of acute ischaemic/preservation injury by an experienced histopathologist blinded to 
any donor details or outcome measures.  None of the glands demonstrated any significant, 
pre-existing underlying pathology. 
 
 
 
Statistical analysis 
Differences in amylase, lipase and insulin levels were analyzed by one-way analysis of 
variance, with post-test analysis using Bonferroni’s multiple comparison test as appropriate. 
All tests were two-tailed and p<0.05 was taken as significant. All analysis was performed 
using GraphPad Prism (GraphPad, La Jolla, CA). 
Results 
Five human pancreases procured but deemed unsuitable for transplantation underwent 
EVNP. Due to the logistics of transport and availability of study members to carry out EVNP, 
the final pancreas had accrued a cold ischemic time of over 30 hours by the time 
normothermic perfusion commenced. Macroscopically both the pancreas and particularly the 
duodenum appeared frankly ischaemic during EVNP. It was therefore felt that this pancreas 
would not provide meaningful data and was excluded from further analysis. The 
characteristics of the remaining four pancreases are shown in table 1. 
Perfusion parameters 
Macroscopically all pancreases appeared well perfused during EVNP (figure 2). Peristalsis 
was observed in the duodenum of the first graft. Pancreatic blood flow remained stable 
throughout perfusion with a mean arterial flow of 35±2.8 mls/min/100g (figure 3). Blood flow 
was highest in the pancreas from the 27-year old DBD donor (table 2). Perfusion of the fourth 
pancreas had to be terminated after 60 minutes because of low perfusate volumes in the 
circuit as a result of excessive drainage from the duodenal catheter. 
Biochemical parameters 
Perfusate amylase and lipase increased in all pancreases during the course of perfusion 
(figure 4 and 5). The increase in perfusate amylase was most marked in the pancreas with 
fatty infiltration from the 46-year old donor, although there were no statistically significant 
differences in mean perfusate amylase (p=0.1011) or mean perfusate lipase (p=0.9088) 
levels between pancreases.  
There were significant differences in mean insulin levels between pancreases (p=0.0199) 
Basal perfusate insulin levels were highest in the pancreas from the 27-year old DBD donor, 
and this was the only pancreas in which insulin secretion was stimulated by a glucose 
challenge (figure 6). Although the pancreases from the 14-year old and 46-year old DBD 
donors did not respond to glucose stimulation, perfusate insulin levels did increase following 
an arginine challenge. The pancreas from the 51-year old DCD donor had the lowest basal 
and glucose-stimulated insulin levels, and mean insulin level was significantly lower than that 
from the 27-year old DBD pancreas (202±30 vs. 2815±839 pmol/L/100g, p<0.05).  
The more in-depth time course of perfusate insulin performed in the second two pancreases 
demonstrated a peak in insulin levels immediately following perfusion, with stable levels 
following this in non-stimulated conditions (figure 7).  
Arterial pH remained within normal limits during the course of perfusion without the need for 
administration of additional bicarbonate (figure 8). 
Histopathological analysis 
Histology from the pancreas from the 27-year old DBD donor post-EVNP showed only very 
focal acinar cell necrosis of the body and tail. The pancreas from the 14-year old DBD 
showed very focal to patchy acinar and fat necrosis distributed throughout the gland. The 
gland from the DCD donor demonstrated similar changes also throughout the gland. Finally, 
the pancreas from the 46-yr old donor showed more extensive parenchymal and fat necrosis 
throughout the gland (figure 9). 
 
 
Discussion 
This is the first report of the use of ex vivo normothermic perfusion to assess the function and 
quality of the human pancreas prior to transplantation. This study demonstrates that the 
technique is technically feasible and that endocrine function is maintained during a short 
period of EVNP. The method allows assessment of blood flow, cellular injury, exocrine and 
endocrine function. The preparation of the pancreas described for EVNP would not 
compromise any implant procedure as the portal vein is not cannulated and the distal portion 
of the iliac Y graft used to secure the arterial cannula can be excised leaving sufficient length 
for anastomosis. The cannulated distal duodenum can also be excised. 
 
At present no objective means to assess pancreas graft quality prior to transplantation is 
available. Axelrod et al have reported a pancreas donor risk index which utilizes 10 donor and 
one transplant characteristic to provide an estimated 1-year pancreas allograft survival (22). 
However, this tool is subject to the limitations of all registry analyses. It is derived 
predominantly from low-risk grafts and only provides a crude estimate of potential graft 
outcome with no reports of the predictive value of the model. It also does not differentiate 
between potential causes of graft loss.  Other studies have reported the use of hypothermic 
machine perfusion to assess the viability of canine segmental pancreatic autografts. Raised 
perfusate amylase levels and lower oxygen extraction were shown to correlate with worse 
pancreas function post transplant (23). Hypothermic machine perfusion has been associated 
with edema and congestion, which increases the risk of early venous thrombosis and graft 
failure (24,25). As such, there is reluctance for its use in clinical pancreas transplantation. 
Tissue level of ATP at the end of cold preservation has also been shown to predict graft 
viability in canine segmental pancreatic autografts (26,27), although the complexity of the 
ATP assays reported limits the clinical utility of these findings.  
 
Clearly it is inappropriate to analyze correlations between donor factors and outcome 
measures during EVNP with such a small sample size. However, there are some interesting 
observations that can be made from the outcome data. Subjectively, the lowest quality 
pancreas was the fatty gland from the 46-year old DBD donor. This pancreas had the highest 
perfusate amylase levels, a marker of cellular injury, and the lowest insulin levels, a marker of 
endocrine function. Furthermore, histology following EVNP demonstrated extensive fat and 
parenchymal necrosis consistent with severe ischemia reperfusion injury. Conversely, the 
pancreas with the highest blood flow and perfusate insulin levels, alongside the least severe 
histological changes, was from the young 27-year old DBD donor. Perhaps unexpectedly, the 
lowest perfusate amylase level was in the pancreas from a DCD donor. However, this 
pancreas was significantly fibrotic and this may have been associated with underlying acinar 
cell loss or dysfunction. It is also surprising that the pancreas from the 14-year old donor did 
not have better endocrine function. Interestingly, this donor was taking high-dose risperidone 
and such antipsychotics have been associated with the development of diabetes (28).  
An initial peak in perfusate insulin was noted immediately after commencement of EVNP in 
the latter two pancreases. This may be the result of insulin diffusing out of β cells during cold 
storage, which is then flushed out of the gland on reperfusion. An insulin surge such as this 
immediately following reperfusion is seen as a marker of injury in clinical pancreas 
transplantation. As such, basal insulin levels are unlikely to be a reliable marker of pancreas 
viability during EVNP. Of more relevance is the insulin response to stimulation as this 
requires active secretion from β cells. It is interesting that two pancreases in this study did not 
respond to glucose stimulation, but did demonstrate insulin secretion in response to additional 
arginine administration, which is known to be a potent stimulant of insulin release in the 
presence of glucose (29). Glucose stimulated insulin secretion is mediated via membrane 
depolarization due to closure of K
+
/ATP channels, whereas arginine depolarizes the cell by a 
different mechanism independent of ATP. Therefore, one explanation for the findings is that 
ATP levels are not sufficient for glucose to initiate adequate membrane depolarization for 
insulin secretion, and that the added depolarization of arginine is required. This warrants 
further investigation.  
There are some concerns about the use of EVNP to assess pancreases prior to 
transplantation. Any organ quality assessment technique should not confer additional damage 
beyond that already sustained during procurement and cold storage. Active pancreatic 
enzymes released from damaged acinar cells are not cleared and will recirculate in the 
perfusate, which may propagate additional pancreatic injury. This damage could potentially 
be limited by the addition of a protease inhibitor such as aprotonin to the perfusate. Moreover, 
much further work is required to determine the most relevant outcome measures. As ischemia 
reperfusion injury and graft pancreatitis, rather than endocrine function, are the clinically 
significant sequelae of using marginal pancreases this should arguably be the focus of further 
investigation. It is of note that this model utilized packed red cells rather than whole blood in 
the perfusate. Therefore many of the mediators of ischemia reperfusion injury, such as 
leukocytes and complement are absent, and the degree of injury seen during EVNP may 
underestimate that which would occur with clinical transplantation. However, it is clearly 
important that EVNP does not confer any additional injury to the gland; indeed, it would be 
ideal if the technique can be used for organ ‘reconditioning’ as well as quality assessment.  In 
this context, comparison of markers of injury between pancreases perfused with whole blood 
or packed red cells may be informative. 
 
Whether parameters during EVNP are reliable predictors that can discriminate suitable from 
unsuitable pancreas grafts will require study of a much larger cohort of organs, work that is 
ongoing in this unit. It is noteworthy that due to logistical constraints, all the pancreases had 
cold ischemic times longer than would be acceptable for clinical transplantation. Such 
durations of cold ischemia are known to potentiate ischemia reperfusion injury (9), and this 
may explain why a degree of necrosis was seen after EVNP in all four pancreases. It is not 
clear the degree to which this necrosis is due to cold ischemic damage or due to damage 
sustained during EVNP. Further studies of EVNP after shorter cold ischemia are required to 
corroborate this. 
 
A significant amount of further work is required before EVNP of the pancreas can be moved 
into the clinical arena. The technique requires optimization to limit any additional injury during 
EVNP, outcome measures during EVNP need to be validated against clinical outcomes and 
the safety of EVNP of the pancreas prior to transplantation established. We are currently 
conducting a series of controlled experiments using EVNP of pig pancreases. Clinical 
translation of these findings will likely also require studies in large animals comparing 
pancreas transplant outcomes following EVNP versus conventional cold storage.  
 
In summary, this is the first report to demonstrate that EVNP of discarded human donor 
pancreases is technically feasible and allows assessment of cellular injury and function. 
Nevertheless, significant refinements to the technique are required before it can be 
considered for clinical use. However, this has the potential to improve the selection of 
pancreases for transplantation, decrease the number of organs that are discarded and 
improve the availability of organs for transplantation. Through organ conditioning and the 
application of cellular and pharmacological interventions it also has the potential to help 
improve outcomes for pancreas transplant recipients. 
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Figure legends 
 
Figure 1. Schematic diagram of circuit used for ex vivo normothermic perfusion.  
 
Figure 2. Pancreas 3 (14-year old DBD) following 30 minutes of EVNP. The duodenal 
contusion is visible. The cannulated iliac Y graft can be seen to the left and the duodenal 
catheter to the bottom right. 
 
Figure 3. Pancreatic blood flow (mls/min/100g) during EVNP. Data are presented as mean ± 
SEM. 
Figure 4. Individual perfusate amylase (U/L) measured from portal vein of pancreas during 
EVNP. 
Figure 5. Individual perfusate lipase (U/L) measured from portal vein of pancreas during 
EVNP. 
Figure 6. Individual perfusate insulin (pmol/L/100g) measured from portal vein of pancreas 
during EVNP under basal, glucose (1g) and arginine (250mg) stimulation. 
Figure 7. Time-course of perfusate insulin levels (pmol/L/100g) measured from portal vein of 
pancreas 3 and pancreas 4 during EVNP. 
Figure 8. Arterial pH during EVNP. Data are presented as mean ± SEM. 
Figure 9. Hematoxylin and eosin stains of pancreas sections following EVNP, showing 
varying degrees of damage. (A) Pancreas 1: 27yr old DBD (very focal acinar cell necrosis); 
(B) Pancreas 2: 51yr old DCD (very focal to patchy acinar cell and fat necrosis); (C) Pancreas 
3: 14yr old DBD (very focal to patchy acinar cell and fat necrosis); (D) Pancreas 4: 46yr old 
DBD (extensive parenchymal and fat necrosis). 
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  Pancreas 1  Pancreas 2  Pancreas 3  Pancreas 4 
Donor type DBD DCD DBD DBD 
Age (years) 27 51 14 46 
Sex Female Female Male Male 
Height (cm) 172 164 184 175 
Weight (kg) 60 63 65 95 
BMI 20.3 23.4 19.2 31.0 
Glucose (mmol/L) 8.4 4.9 8.5 8 
Amylase (iU/L) 40 322 147 104 
Cause of death 
Hypoxic brain 
damage 
Intra-cerebral 
hemorrhage  
Traumatic 
brain injury 
ICH; grade 4 
glioblastoma 
Length of hospital stay 
prior to procurement 
(hrs) 47 44 79 22 
Smoker Yes Yes Yes No 
Excess alcohol use No Yes No No 
Family history of 
diabetes No Yes No No 
Reason not 
transplanted 
Parenchymal 
injury 
Pancreas 
fibrotic 
Duodenal 
contusion 
Fatty infiltration 
and calcification 
Time between 
withdrawal of treatment 
and cardiac death 
(mins) N/A 24 N/A N/A 
Time between cardiac 
death and cold 
perfusion (mins) 0 14 0 0 
Cold Ischemic time 16 hrs 35 mins 18 hrs 34 mins 13 hrs 23 mins 13 hrs 14 mins 
Preservation solution 
for initial in-situ cold 
perfusion 
University of 
Wisconsin 
University of 
Wisconsin 
University of 
Wisconsin 
University of 
Wisconsin 
EVNP duration (mins) 120 120 120 60 
 
Table 1. Donor characteristics of discarded human pancreases undergoing EVNP. DBD, 
donation after brain death; DCD, donation after cardiac death. 
  
 Pancreas 1 Pancreas 2 Pancreas 3 Pancreas 4 
Mean bloodflow 
(mls/min/100g) 
50 ±6.3 32 ±2.6 28 ±2.4 33 ±3.5 
Mean perfusate amylase 
(iU/L) 
582 ±127.2 185 ±52.2 198 ±31.1 1525 ±457 
AUC perfusate amylase (iU/L) 1748 455 844 4680 
Mean perfusate lipase (iU/L) 6352 ±2092 2168 ±704.5 6199 ±645.5 7960 
AUC perfusate lipase (iU/L) 8490 2908 8981  
Mean pH No data 7.36 ±0.04 7.45 ±0.02 7.31 ±0.11 
Perfusate insulin/100g 
(pmol/L) 
Basal 
Glucose-stimulated 
Arginine-stimulated 
 
1976 
3654 
No data 
 
172 
232 
No data 
 
1029 
940 
1777 
 
892 
750 
1306 
Duodenal drainage (ml) 80 85 100 390 
 
Table 2. Outcome measures during EVNP of discarded human pancreases. Data are 
presented as mean±SEM unless otherwise indicated. 
  
  
Figure 1. Schematic diagram of circuit used for ex vivo normothermic perfusion. 
  
  
Figure 2. Pancreas 3 (14-year old DBD) following 30 minutes of EVNP. The duodenal 
contusion is visible. The cannulated iliac Y graft can be seen to the left and the duodenal 
catheter to the bottom right.  
  
  
Figure 3. Pancreatic blood flow (mls/min/100g) during EVNP. Data are presented as mean ± 
SEM. 
  
  
Figure 4. Individual perfusate amylase (U/L) measured from portal vein of pancreas during 
EVNP. 
  
  
Figure 5. Individual perfusate lipase (U/L) measured from portal vein of pancreas during 
EVNP. 
  
  
 
 
Figure 6. Individual perfusate insulin (pmol/L/100g) measured from portal vein of pancreas 
during EVNP under basal, glucose (1g) and arginine (250mg) stimulation.  
  
  
 
Figure 7. Time-course of perfusate insulin levels (pmol/L/100g) measured from portal vein of 
pancreas 3 and pancreas 4 during EVNP. 
  
  
Figure 8. Arterial pH during EVNP. Data are presented as mean ± SEM. 
  
 (A)  (B)  
(C)  (D)  
Figure 9. Hematoxylin and eosin stains of pancreas sections following EVNP, showing 
varying degrees of damage. (A) Pancreas 1: 27yr old DBD (very focal acinar cell necrosis); 
(B) Pancreas 2: 51yr old DCD (very focal to patchy acinar cell and fat necrosis); (C) Pancreas 
3: 14yr old DBD (very focal to patchy acinar cell and fat necrosis); (D) Pancreas 4: 46yr old 
DBD (extensive parenchymal and fat necrosis). 
 
 
 
